ContextVision reaches another top position in a prestigious competition using deep learning in digital pathology

STOCKHOLM – May 17, 2018, – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, placed second in a renowned international competition on automated image analysis called the Camelyon Challenge.

The competition was initially held last year but has since opened for resubmissions. Following the submission by ContextVision on Monday, the results were published on the Camelyon Challenge website.

The Camelyon Challenge focuses on automated detection and classification of breast cancer metastases in whole-slide images of histological lymph node sections. This task has high clinical relevance and would normally require extensive microscopic assessment by pathologists.

We chose this challenge as it is relevant for our new business area, digital pathology. These results really demonstrates our capacity to apply deep learning to complex images and produce highly accurate results,” said Anita Tollstadius, CEO of ContextVision.

Participating teams were given the same dataset of whole slide images. Many prestigious teams participated, including both highly-reputable academic teams and research groups from large companies.

This proves that we are highly competitive and we continue the development of new spearheading products with great confidence. We intend to deliver new, highly accurate products that ultimately leads to improvement of care for cancer patients,” said Tollstadius.

 

For further information, please contact ContextVision’s CEO, Anita Tollstadius, cell: +46 70 337 30 26 email: Anita.Tollstadius@contextvision.se or visit www.contextvision.com

 


About ContextVision
ContextVision is a medical technology software company that specializes in image analysis and artificial intelligence. ContextVision is the global market leader within image enhancement and is a software partner to leading medical imaging manufacturers all over the world. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
As an industry pioneer for more than 30 years, ContextVision is significantly investing in R&D to develop new applications of the latest artificial intelligence technologies and expanding into the growing digital pathology market. The release of its first product, supporting the diagnosis of prostate cancer, is planned in the near future.
The company is based in Sweden, with local representation in the U.S., Russia, Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.
For more information please visit www.contextvision.com